| MeSH term | MeSH ID | Detail |
|---|---|---|
| Lung Neoplasms | D008175 | 171 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Wong WM et al. | Standard treatment for Helicobacter pylori infection is suboptimal in non-ulcer dyspepsia compared with duodenal ulcer in Chinese. | 2005 | Aliment. Pharmacol. Ther. | pmid:15644048 |
| Hurenkamp GJ et al. | Equally high efficacy of 4, 7 and 10-day triple therapies to eradicate Helicobacter pylori infection in patients with ulcer disease. | 2000 | Aliment. Pharmacol. Ther. | pmid:10930901 |
| Lai KC et al. | Ulcer-healing drugs are required after eradication of Helicobacter pylori in patients with gastric ulcer but not duodenal ulcer haemorrhage. | 2000 | Aliment. Pharmacol. Ther. | pmid:10930902 |
| Pilotto A et al. | Pantoprazole versus one-week Helicobacter pylori eradication therapy for the prevention of acute NSAID-related gastroduodenal damage in elderly subjects. | 2000 | Aliment. Pharmacol. Ther. | pmid:10930903 |
| Kihira K et al. | Rabeprazole, amoxycillin and low- or high-dose clarithromycin for cure of Helicobacter pylori infection. | 2000 | Aliment. Pharmacol. Ther. | pmid:10930904 |
| Kamada T et al. | Cetraxate, a mucosal protective agent, combined with omeprazole, amoxycillin, and clarithromycin increases the eradication rate of helicobacter pylori in smokers. | 2000 | Aliment. Pharmacol. Ther. | pmid:10930905 |
| Wong WM et al. | Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection. | 2003 | Aliment. Pharmacol. Ther. | pmid:12622764 |
| Fischbach L and Evans EL | Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. | 2007 | Aliment. Pharmacol. Ther. | pmid:17635369 |
| Meier R et al. | Fish oil (Eicosapen) is less effective than metronidazole, in combination with pantoprazole and clarithromycin, for Helicobacter pylori eradication. | 2001 | Aliment. Pharmacol. Ther. | pmid:11380323 |
| Spinzi G et al. | Randomized study comparing omeprazole plus amoxycillin versus omeprazole plus clarithromycin for eradication of Helicobacter pylori. | 1997 | Aliment. Pharmacol. Ther. | pmid:9146769 |
| Peterson WL | The role of antisecretory drugs in the treatment of Helicobacter pylori infection. | 1997 | Aliment. Pharmacol. Ther. | pmid:9146787 |
| Kaneko F et al. | High prevalence rate of Helicobacter pylori resistance to clarithromycin during long-term multiple antibiotic therapy for chronic respiratory disease caused by non-tuberculous mycobacteria. | 2004 | Aliment. Pharmacol. Ther. | pmid:15298607 |
| Sierra F et al. | Pilot study: miscellaneous therapy is highly successful for Helicobacter pylori eradication. | 2013 | Aliment. Pharmacol. Ther. | pmid:23656465 |
| Masaoka T et al. | Second-line treatment of Helicobacter pylori infection after dilution agar methods and PCR-RFLP analysis. | 2004 | Aliment. Pharmacol. Ther. | pmid:15298608 |
| Kondo Y et al. | Helicobacter pylori eradication decreases blood neutrophil and monocyte counts. | 2004 | Aliment. Pharmacol. Ther. | pmid:15298609 |
| Chiba N et al. | Economic evaluation of Helicobacter pylori eradication in the CADET-Hp randomized controlled trial of H. pylori-positive primary care patients with uninvestigated dyspepsia. | 2004 | Aliment. Pharmacol. Ther. | pmid:14984382 |
| de Francesco V et al. | Primary clarithromycin resistance in Italy assessed on Helicobacter pylori DNA sequences by TaqMan real-time polymerase chain reaction. | 2006 | Aliment. Pharmacol. Ther. | pmid:16423002 |
| Di Mario F et al. | Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study. | 2006 | Aliment. Pharmacol. Ther. | pmid:16611285 |
| Madisch A et al. | Healing of lymphocytic gastritis after Helicobacter pylori eradication therapy--a randomized, double-blind, placebo-controlled multicentre trial. | 2006 | Aliment. Pharmacol. Ther. | pmid:16441467 |
| Borody TJ et al. | Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection. | 2006 | Aliment. Pharmacol. Ther. | pmid:16441468 |
| Laine L | Review article: esomeprazole in the treatment of Helicobacter pylori. | 2002 | Aliment. Pharmacol. Ther. | pmid:12047270 |
| Molina-Infante J et al. | Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. | 2015 | Aliment. Pharmacol. Ther. | pmid:25776067 |
| Wong BC et al. | One-week ranitidine bismuth citrate-based triple therapy for the eradication of Helicobacter pylori in Hong Kong with high prevalence of metronidazole resistance. | 2001 | Aliment. Pharmacol. Ther. | pmid:11207516 |
| Fakheri H et al. | Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate. | 2001 | Aliment. Pharmacol. Ther. | pmid:11207517 |
| Nagahara A et al. | Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection. | 2001 | Aliment. Pharmacol. Ther. | pmid:11207518 |
| Bardhan KD et al. | Triple therapy for Helicobacter pylori eradication: a comparison of pantoprazole once versus twice daily. | 2000 | Aliment. Pharmacol. Ther. | pmid:10632646 |
| Cammarota G et al. | Five-day regimens containing ranitidine bismuth citrate plus high-dose clarithromycin and either amoxycillin or tinidazole for Helicobacter pylori infection. | 2000 | Aliment. Pharmacol. Ther. | pmid:10632648 |
| Shokri-Shirvani J et al. | Letter: global emergence of Helicobacter pylori antibiotic resistance - unanswered questions. | 2016 | Aliment. Pharmacol. Ther. | pmid:27137738 |
| Park HG et al. | Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naïve patients. | 2012 | Aliment. Pharmacol. Ther. | pmid:22066530 |
| Poon SK et al. | Primary resistance to antibiotics and its clinical impact on the efficacy of Helicobacter pylori lansoprazole-based triple therapies. | 2002 | Aliment. Pharmacol. Ther. | pmid:11860412 |
| Peitz U et al. | High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study. | 2002 | Aliment. Pharmacol. Ther. | pmid:11860415 |
| Sheu BS et al. | Impact of supplement with Lactobacillus- and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication. | 2002 | Aliment. Pharmacol. Ther. | pmid:12197847 |
| Calvet X et al. | One-week triple vs. quadruple therapy for Helicobacter pylori infection - a randomized trial. | 2002 | Aliment. Pharmacol. Ther. | pmid:12144575 |
| Calvet X et al. | A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. | 2000 | Aliment. Pharmacol. Ther. | pmid:10792124 |
| Spinzi GC et al. | Comparison of omeprazole and lansoprazole in short-term triple therapy for Helicobacter pylori infection. | 1998 | Aliment. Pharmacol. Ther. | pmid:9663722 |
| O'Connor HJ et al. | Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough? | 1998 | Aliment. Pharmacol. Ther. | pmid:9570262 |
| Goodgame RW et al. | Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohn's disease. | 2001 | Aliment. Pharmacol. Ther. | pmid:11736715 |
| Malfertheiner P et al. | Helicobacter pylori eradication and gastric ulcer healing--comparison of three pantoprazole-based triple therapies. | 2003 | Aliment. Pharmacol. Ther. | pmid:12752349 |
| Gené E et al. | Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. | 2003 | Aliment. Pharmacol. Ther. | pmid:12752350 |
| Canducci F et al. | A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. | 2000 | Aliment. Pharmacol. Ther. | pmid:11121911 |
| Toracchio S et al. | Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication. | 2000 | Aliment. Pharmacol. Ther. | pmid:11121913 |
| Cammarota G et al. | Helicobacter pylori eradication using one-week low-dose lansoprazole plus amoxycillin and either clarithromycin or azithromycin. | 1996 | Aliment. Pharmacol. Ther. | pmid:8971300 |
| Vcev A et al. | Pantoprazole, amoxycillin and either azithromycin or clarithromycin for eradication of Helicobacter pylori in duodenal ulcer. | 2000 | Aliment. Pharmacol. Ther. | pmid:10632647 |
| Gisbert JP et al. | Recurrence of Helicobacter pylori infection after several eradication therapies: long-term follow-up of 1000 patients. | 2006 | Aliment. Pharmacol. Ther. | pmid:16556172 |
| Gomollón F et al. | Third line treatment for Helicobacter pylori: a prospective, culture-guided study in peptic ulcer patients. | 2000 | Aliment. Pharmacol. Ther. | pmid:11012479 |
| Jung YS et al. | Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. | 2017 | Aliment. Pharmacol. Ther. | pmid:28497487 |
| De Francesco V et al. | Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure. | 2004 | Aliment. Pharmacol. Ther. | pmid:14871280 |
| Klok RM et al. | Continued utilization and costs of proton pump inhibitors after Helicobacter pylori eradication in chronic users of gastrointestinal drugs. | 2002 | Aliment. Pharmacol. Ther. | pmid:11966514 |
| Gisbert JP et al. | Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures. | 2012 | Aliment. Pharmacol. Ther. | pmid:22372560 |
| Graham DY et al. | Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication. | 2003 | Aliment. Pharmacol. Ther. | pmid:12755836 |